# Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases

> **NCT06548607** · EARLY_PHASE1 · RECRUITING · sponsor: **Nanjing Bioheng Biotech Co., Ltd.** · enrollment: 20 (estimated)

## Conditions studied

- SLE (Systemic Lupus)
- Systemic Sclerosis
- ANCA Associated Vasculitis
- Idiopathic Inflammatory Myopathies
- Sjogren's Syndrome
- Autoimmune Diseases

## Interventions

- **DRUG:** CD19 or CD19-BCMA CAR-T

## Key facts

- **NCT ID:** NCT06548607
- **Lead sponsor:** Nanjing Bioheng Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-14
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06548607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06548607, "Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06548607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*